Foresite Capital Management VI LLC
Position in DNLI — Denali Therapeutics Inc.
CIK 2013341
WEST HOLLYWOOD, CA
Position in DNLI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$35,924,950
+$12,693,507 QoQ
Shares Held
1,396,771
+15.4% QoQ
Ownership
0.874%
of shares outstanding
% of Portfolio
5.59%
of 13F equity value
Holder Rank
#26
of 290 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Foresite Capital Management VI LLC holds $621,072,779 across 21 Biotechnology names. DNLI ranks #4 (5.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CGON |
CG Oncology, Inc.
|
2,369,574 | $168,358,232 | |
| 2 | ALMS |
Alumis Inc.
|
4,247,670 | $119,529,433 | |
| 3 | SPTX |
Seaport Therapeutics, Inc.
|
1,779,521 | $38,651,196 | |
| 4 | DNLI |
Denali Therapeutics Inc.
This page
|
1,396,771 | $35,924,950 | |
| 5 | CLDX |
Celldex Therapeutics, Inc.
|
879,713 | $32,734,120 | |
| 6 | AGIO |
Agios Pharmaceuticals, Inc.
|
785,000 | $29,131,350 | |
| 7 | CRVS |
Corvus Pharmaceuticals, Inc.
|
1,831,233 | $27,358,621 | |
| 8 | PBLS |
Parabilis Medicines, Inc.
|
999,044 | $27,343,834 |
All Filings in DNLI
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $35,924,950 | 1,396,771 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $23,231,443 | 1,209,971 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $16,510,000 | 1,000,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $14,520,000 | 1,000,000 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||